Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.

Garofalo, Cecilia; Capristo, Mariantonietta; Mancarella, Caterina; Reunevi, Hadas; Picci, Piero; Scotlandi, Katia.

Afiliação

Garofalo C; Experimental Oncology Laboratory, CRS Development of Biomolecular Therapies, Rizzoli Institute , Bologna , Italy.
Capristo M; Experimental Oncology Laboratory, CRS Development of Biomolecular Therapies, Rizzoli Institute , Bologna , Italy.
Mancarella C; Experimental Oncology Laboratory, CRS Development of Biomolecular Therapies, Rizzoli Institute , Bologna , Italy.
Reunevi H; TyrNovo Ltd. , Tel Aviv , Israel.
Picci P; Experimental Oncology Laboratory, CRS Development of Biomolecular Therapies, Rizzoli Institute , Bologna , Italy.
Scotlandi K; Experimental Oncology Laboratory, CRS Development of Biomolecular Therapies, Rizzoli Institute , Bologna , Italy.

Front Endocrinol (Lausanne) ; 6: 74, 2015.

Article em En | MEDLINE | ID: mdl-26029165